Ignite Creation Date:
2024-05-06 @ 2:02 PM
Last Modification Date:
2024-10-26 @ 1:24 PM
Study NCT ID:
NCT04194632
Status:
UNKNOWN
Last Update Posted:
2021-05-03
First Post:
2019-12-09
Brief Title:
Right Ventricular Pacing in Pulmonary Arterial Hypertension
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Study Overview
Official Title:
Right Ventricular Pacing to Treat Right Ventricular Failure A Single Arm Hemodynamic Study
Status:
UNKNOWN
Status Verified Date:
2021-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In pulmonary arterial hypertension PAH progressive pulmonary vascular remodeling leads to supraphysiologic right ventricular RV afterload Pharmacologic trials have shown that aggressive upfront treatment reversing pulmonary vascular remodeling successfully increases RV function and improves survival To date however there are no proven treatments that target RV contractile function
Echocardiographic studies of RV dysfunction in the setting of pressure overload have demonstrated intra and interventricular dyssynchrony even in the absence of overt right bundle branch block RBBB
Electrophysiologic studies of patients with chronic thromboembolic disease CTEPH at the time of pulmonary endarterectomy have shown prolongation of action potential and slowed conduction in the right ventricle which has correlated with echocardiographic measures of dyssynchrony
Cardiac MRI measures of RV strain in patients with PAH demonstrated simultaneous initiation of RV and left ventricular LV contraction but delayed peak RV strain suggesting that interventricular dyssynchrony is a mechanical rather than electrical phenomenon
Prior studies of RV dysfunction in an animal model computer model congenital heart disease and CTEPH have suggested acute hemodynamic benefits of RV pacing However RV pacing has not been studied in patients with PAH Furthermore it remains unclear if pacing particular regions of the RV can achieve a hemodynamic benefit and what cost this hemodynamic improvement may incur with regards to myocardial energetics and wall stress
Therefore the investigators propose to examine RV electrical activation in PAH map the area of latest activation and then evaluate the hemodynamic and energetic effects of RV pacing in these patients
Echocardiographic studies of RV dysfunction in the setting of pressure overload have demonstrated intra and interventricular dyssynchrony even in the absence of overt right bundle branch block RBBB
Electrophysiologic studies of patients with chronic thromboembolic disease CTEPH at the time of pulmonary endarterectomy have shown prolongation of action potential and slowed conduction in the right ventricle which has correlated with echocardiographic measures of dyssynchrony
Cardiac MRI measures of RV strain in patients with PAH demonstrated simultaneous initiation of RV and left ventricular LV contraction but delayed peak RV strain suggesting that interventricular dyssynchrony is a mechanical rather than electrical phenomenon
Prior studies of RV dysfunction in an animal model computer model congenital heart disease and CTEPH have suggested acute hemodynamic benefits of RV pacing However RV pacing has not been studied in patients with PAH Furthermore it remains unclear if pacing particular regions of the RV can achieve a hemodynamic benefit and what cost this hemodynamic improvement may incur with regards to myocardial energetics and wall stress
Therefore the investigators propose to examine RV electrical activation in PAH map the area of latest activation and then evaluate the hemodynamic and energetic effects of RV pacing in these patients
Detailed Description:
Research procedures in chronological order
1 Baseline clinical variables will be prospectively determined and then obtained retrospectively from the clinical assessment of individual pulmonary hypertension team physicians via chart review The most recent transthoracic echocardiogram will also be evaluated and routine clinical variables including tricuspid annular plane systolic excursion TAPSE RV fractional area change FAC RV outflow tract OT and LVOT velocity time integral VTI and ejection fraction EF will be extracted
2 All patients will have cardiac MRI performed prior to the procedure to allow precise measurement of right ventricular volumes as well as LV volumes RVEF and LVEF Gadolinium enhancement using gadolinium contrast will be measured
3 Standard of care right heart catheterization RHC will be performed on the day of the research procedure
4 Radial arterial pressure will be used for periprocedural monitoring as well as for sampling of arterial oxygen content and arterial oxygen lactate
5 Myocardial energetics will be assessed via sampling of coronary sinus venous blood with measurement of oxygen saturation and lactate
6 Following the standard of care RHC endocardial mapping will be performed After pressure-volume measurements are obtained step 7 pacing will be performed from the right atrium RA His bundle and RV at the site of the latest activation with repeat measurements of pressure-volume relationships
7 Once endocardial mapping is complete a 7-French Millar conductance catheter will be placed into the RV and used to obtain pressure-volume data for the RV using the INCA PV signal processor The Valsalva maneuver will be used to generate a series of PV-loops reflecting preload reduction subsequently allowing for the calculation of a load independent measure of contractility the end systolic pressure volume relationship Ees RV afterload will be measured as effective arterial elastance Ea and V-A coupling will be assessed by the ratio of EesEa Myocardial energetics will be assessed via PV area PVA and calculation of the transmyocardial arteriovenous oxygen extraction
1 Baseline clinical variables will be prospectively determined and then obtained retrospectively from the clinical assessment of individual pulmonary hypertension team physicians via chart review The most recent transthoracic echocardiogram will also be evaluated and routine clinical variables including tricuspid annular plane systolic excursion TAPSE RV fractional area change FAC RV outflow tract OT and LVOT velocity time integral VTI and ejection fraction EF will be extracted
2 All patients will have cardiac MRI performed prior to the procedure to allow precise measurement of right ventricular volumes as well as LV volumes RVEF and LVEF Gadolinium enhancement using gadolinium contrast will be measured
3 Standard of care right heart catheterization RHC will be performed on the day of the research procedure
4 Radial arterial pressure will be used for periprocedural monitoring as well as for sampling of arterial oxygen content and arterial oxygen lactate
5 Myocardial energetics will be assessed via sampling of coronary sinus venous blood with measurement of oxygen saturation and lactate
6 Following the standard of care RHC endocardial mapping will be performed After pressure-volume measurements are obtained step 7 pacing will be performed from the right atrium RA His bundle and RV at the site of the latest activation with repeat measurements of pressure-volume relationships
7 Once endocardial mapping is complete a 7-French Millar conductance catheter will be placed into the RV and used to obtain pressure-volume data for the RV using the INCA PV signal processor The Valsalva maneuver will be used to generate a series of PV-loops reflecting preload reduction subsequently allowing for the calculation of a load independent measure of contractility the end systolic pressure volume relationship Ees RV afterload will be measured as effective arterial elastance Ea and V-A coupling will be assessed by the ratio of EesEa Myocardial energetics will be assessed via PV area PVA and calculation of the transmyocardial arteriovenous oxygen extraction
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None